Rockefeller Capital Management L.P. Grows Holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Rockefeller Capital Management L.P. grew its stake in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 323.1% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 281,922 shares of the company’s stock after purchasing an additional 215,283 shares during the quarter. Rockefeller Capital Management L.P. owned approximately 0.07% of Recursion Pharmaceuticals worth $1,906,000 at the end of the most recent quarter.

Other institutional investors also recently added to or reduced their stakes in the company. Jaffetilchin Investment Partners LLC bought a new stake in Recursion Pharmaceuticals during the 4th quarter valued at $147,000. Capital Fund Management S.A. bought a new stake in shares of Recursion Pharmaceuticals in the fourth quarter valued at about $1,242,000. Raymond James Financial Inc. purchased a new stake in Recursion Pharmaceuticals in the fourth quarter worth about $609,000. Advisory Services Network LLC bought a new position in Recursion Pharmaceuticals during the 4th quarter worth about $74,000. Finally, Rathbones Group PLC purchased a new position in Recursion Pharmaceuticals during the 4th quarter valued at about $69,000. Hedge funds and other institutional investors own 89.06% of the company’s stock.

Recursion Pharmaceuticals Trading Up 3.4 %

Recursion Pharmaceuticals stock opened at $5.50 on Monday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.35 and a current ratio of 4.35. The stock has a market cap of $2.21 billion, a PE ratio of -3.59 and a beta of 1.00. The stock has a 50-day moving average of $6.62 and a two-hundred day moving average of $6.80. Recursion Pharmaceuticals, Inc. has a one year low of $3.79 and a one year high of $12.36.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its quarterly earnings data on Friday, February 28th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.17). Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The company had revenue of $4.60 million during the quarter, compared to analysts’ expectations of $19.04 million. During the same period in the previous year, the business earned ($0.42) earnings per share. The business’s revenue for the quarter was down 57.8% compared to the same quarter last year. On average, research analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on RXRX. Needham & Company LLC reaffirmed a “buy” rating and issued a $11.00 price target on shares of Recursion Pharmaceuticals in a research report on Tuesday, April 8th. Cowen reiterated a “hold” rating on shares of Recursion Pharmaceuticals in a report on Friday, February 28th. Morgan Stanley decreased their price objective on Recursion Pharmaceuticals from $10.00 to $8.00 and set an “equal weight” rating for the company in a research note on Thursday, April 10th. Leerink Partners cut their target price on Recursion Pharmaceuticals from $7.00 to $6.00 and set a “market perform” rating on the stock in a research note on Friday, February 28th. Finally, KeyCorp decreased their price target on shares of Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating for the company in a research report on Wednesday, January 8th. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, Recursion Pharmaceuticals has an average rating of “Hold” and a consensus target price of $8.20.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.